Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixion 2.0: FX06 in Acute Respiratory Distress Syndrome
2024-519104-27-00Phase 2Completed
- Sponsor
- F4 Pharma
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing FX06 with Placebo (2 arms). Primary endpoint: Time to initial unassisted breathing (UAB) until day 28. Started Nov 2024; status: completed.
02
Drugs
FX06
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-519104-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519104-27-00.